Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

NCT06566079 is registered in ClinicalTrials.gov with InSilico Medicine Hong Kong Limited as lead sponsor.

NCT NCT06566079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06566079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
Lead sponsor
InSilico Medicine Hong Kong Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 27, 2024
Completion date
February 28, 2028
Enrollment
160 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, malignant mesothelioma, metastatic malignant solid tumor